Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Li, Junlin ^a   Zhou, Binhua P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BETA CATENIN; HERMES ANTIGEN; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; ISOENZYME; NUCLEAR PROTEIN; RETINAL DEHYDROGENASE; TWIST1 PROTEIN, HUMAN; WNT PROTEIN; WNT3 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL MOTILITY; CELL STRAIN MCF 7; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC CORRELATION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD44; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; ISOENZYMES; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RETINAL DEHYDROGENASE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; TWIST TRANSCRIPTION FACTOR; WNT PROTEINS;

EID: 79351468712     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-49     Document Type: Article

References (35)

1. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648. 10.1038/367645a0, 7509044.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
3. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. British journal of cancer 2008, 98(4):756-765. 10.1038/sj.bjc.6604242, 2259168, 18268494.
4. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25(12):1696-1708. 10.1038/sj.onc.1209327, 16449977.
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401. 10.1038/nature03128, 15549107.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-115. 10.1038/nature05384, 17122771.
7. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer research 2007, 67(3):1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
8. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell 2007, 1(3):313-323. 10.1016/j.stem.2007.06.002, 18371365.
9. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106(33):13820-13825. 10.1073/pnas.0905718106, 19666588.
10. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284. 10.1038/nrc1590, 15803154.
11. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100(9):672-679. 10.1093/jnci/djn123, 18445819.
12. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27(9):2059-2068. 10.1002/stem.154, 19544473.
13. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
14. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3(8):e2888. 10.1371/journal.pone.0002888, 2492808, 18682804.
15. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009, 69(7):2887-2895. 10.1158/0008-5472.CAN-08-3343, 2664865, 19276366.
16. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428. 10.1172/JCI39104, 2689101, 19487818.
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
18. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008, 40(7):643-650. 10.1111/j.1745-7270.2008.00443.x, 2740620, 18604456.
19. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 2720409, 19666588.
20. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005, 17(5):499-508. 10.1016/j.ceb.2005.08.014, 16107313.
21. Junghans D, Haas IG, Kemler R. Mammalian cadherins and protocadherins: about cell death, synapses and processing. Curr Opin Cell Biol 2005, 17(5):446-452. 10.1016/j.ceb.2005.08.008, 16099637.
22. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480. 10.1016/j.cell.2006.10.018, 17081971.
23. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007, 67(5):2089-2097. 10.1158/0008-5472.CAN-06-3625, 17332338.
24. Abmayr SM, Yao T, Parmely T, Workman JL. Preparation of nuclear and cytoplasmic extracts from mammalian cells. Curr Protoc Mol Biol 2006, Chapter 12(Unit 12):11.
25. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003, 423(6938):448-452. 10.1038/nature01611, 12717451.
26. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008, 68(10):3655-3661. 10.1158/0008-5472.CAN-07-2940, 18483247.
27. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999, 154(2):515-523. 10.1016/S0002-9440(10)65297-2, 1850011, 10027409.
28. Masaki T, Goto A, Sugiyama M, Matsuoka H, Abe N, Sakamoto A, Atomi Y. Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 2001, 92(10):2539-2546. 10.1002/1097-0142(20011115)92:10<2539::AID-CNCR1605>3.0.CO;2-I, 11745187.
29. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67(5):1979-1987. 10.1158/0008-5472.CAN-06-1479, 17332325.
30. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6(10):931-940. 10.1038/ncb1173, 15448698.
31. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998, 19(4):379-383. 10.1038/1270, 9697701.
32. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009, 19(6):683-697. 10.1038/cr.2009.43, 19365403.
33. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108(6):837-847. 10.1016/S0092-8674(02)00685-2, 11955436.
34. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002, 26(5):463-476. 10.1006/cbir.2002.0901, 12095232.
35. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138(4):645-659. 10.1016/j.cell.2009.06.034, 19682730.